Results 171 to 180 of about 138,725 (257)

JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events. [PDF]

PLoS One
Gurevic I, Meudec L, Mariette X, Nocturne G, McCoy SS.   +4 more
europepmc   +1 more source

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. [PDF]

Nat Med
Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Álvarez-Larrán A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN, Mascarenhas J.   +27 more
europepmc   +1 more source

RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. [PDF]

J Am Chem Soc
Rafic E, Ma C, Shih BB, Miller H, Yuste R, Palomero T, Etchenique R.   +6 more
europepmc   +1 more source

Efficacy of Tapering Biologics and JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-analysis [PDF]

Sandra Rotea-Salvo, Laura Galindo-Dominguez, Belén Vera, Vanesa Balboa‐Barreiro, Luis Ramudo, Maite Silva-Díaz, N. Oreiro-Villar, Francisco Javier de Toro Santos, Isabel Martín‐Herranz, Francisco J. Blanco   +9 more
openalex   +1 more source

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency. [PDF]

Front Immunol
Roppelt A, Markina U, Beloglazova I, Parshin V, Kanner D, Pershin D, Fadeeva M, Raykina E, Aleksenko M, Karaulov A, Lysenko M, Fomina D.   +11 more
europepmc   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. [PDF]

Future Oncol
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, SENTRY investigators.   +10 more
europepmc   +1 more source

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review.

Böll, Simone Lisa, Seyed Jafari, Seyed Morteza, Conrad, Curdin, Schlapbach, Christoph   +3 more
openalex   +1 more source

Cryptococcosis in a patient with rheumatoid arthritis following glucocorticoid and JAK inhibitor therapy: a case description on stabilization with tocilizumab. [PDF]

Quant Imaging Med Surg
Zhou M, Guan H, Huang Y, Yuan F.
europepmc   +1 more source

Discovery of 5-Chloro-N²-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway

, 2010
Stephanos Ioannidis, Michelle L. Lamb, Tao Wang, Lynsie Almeida, M. Block, Audrey M. Davies, Bo Peng, Mei Su, Haijun Zhang, Ethan Hoffmann, Caroline Rivard, Isabelle Green, Tina Howard, Hannah Pollard, Jon Read, Marat Alimzhanov, Geraldine Bebernitz, Kirsten Bell, Minwei Ye, Dennis Huszar, Michael Zinda   +20 more
openalex   +1 more source

Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta-Analysis. [PDF]

Arthritis Care Res (Hoboken)
Sathapanasiri T, Meraz M, Mokri H, K Veettil S, Wijarnpreecha K, Schlesinger N, Kavanaugh A, Chaiyakunapruk N.   +7 more
europepmc   +1 more source